{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=mirabegron+50+mg&page=2",
    "query": {
      "intervention": "mirabegron 50 mg",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 30,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=mirabegron+50+mg&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=mirabegron+50+mg&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T02:36:15.243Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02045862",
      "title": "A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Bladder Overactive",
        "Overactive Bladder",
        "Urgency Incontinence",
        "Urinary Bladder Diseases\\Urologic Diseases"
      ],
      "interventions": [
        {
          "name": "Solifenacin succinate",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match solifenacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match mirabegron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Europe B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1829,
      "start_date": "2014-03-17",
      "completion_date": "2016-09-08",
      "has_results": true,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-10-02T02:36:15.243Z",
      "location_count": 75,
      "location_summary": "Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02045862"
    },
    {
      "nct_id": "NCT05604222",
      "title": "Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Urgency Urinary Incontinence",
        "Nocturia"
      ],
      "interventions": [
        {
          "name": "Mirabegron 50 MG",
          "type": "DRUG"
        },
        {
          "name": "Brief Behavioral Treatment for Insomnia",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Shachi Tyagi",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "60 Years and older · Female only"
      },
      "enrollment_count": 120,
      "start_date": "2023-03-05",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-02T02:36:15.243Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05604222"
    },
    {
      "nct_id": "NCT02462837",
      "title": "Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urinary Bladder, Overactive",
        "Pain",
        "Lower Urinary Tract Symptoms"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southern Illinois University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2015-05",
      "completion_date": "2019-01-30",
      "has_results": true,
      "last_update_posted_date": "2023-06-13",
      "last_synced_at": "2026-10-02T02:36:15.243Z",
      "location_count": 1,
      "location_summary": "Springfield, Illinois",
      "locations": [
        {
          "city": "Springfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02462837"
    },
    {
      "nct_id": "NCT03049462",
      "title": "The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "B Complex Plus Vitamin C Tablets",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 55,
      "start_date": "2017-03-13",
      "completion_date": "2026-08-26",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-02T02:36:15.243Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03049462"
    },
    {
      "nct_id": "NCT02981459",
      "title": "Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Urinary Frequency/Urgency",
        "Bladder Irritable",
        "Bladder Pain Syndrome"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 89 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2017-12-08",
      "completion_date": "2018-06",
      "has_results": false,
      "last_update_posted_date": "2020-10-22",
      "last_synced_at": "2026-10-02T02:36:15.243Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02981459"
    },
    {
      "nct_id": "NCT02092181",
      "title": "A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinsons Disease"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daniel Burdick, MD",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-03",
      "completion_date": "2018-07-01",
      "has_results": true,
      "last_update_posted_date": "2021-08-16",
      "last_synced_at": "2026-10-02T02:36:15.243Z",
      "location_count": 1,
      "location_summary": "Kirkland, Washington",
      "locations": [
        {
          "city": "Kirkland",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02092181"
    },
    {
      "nct_id": "NCT02216214",
      "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Overactive Bladder (OAB)"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 888,
      "start_date": "2014-10-07",
      "completion_date": "2018-01-02",
      "has_results": true,
      "last_update_posted_date": "2024-11-22",
      "last_synced_at": "2026-10-02T02:36:15.243Z",
      "location_count": 103,
      "location_summary": "Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 88 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02216214"
    },
    {
      "nct_id": "NCT03411252",
      "title": "Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Achalasia"
      ],
      "interventions": [
        {
          "name": "Mirabegron 50 MG",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 5,
      "start_date": "2018-02-15",
      "completion_date": "2019-12-15",
      "has_results": false,
      "last_update_posted_date": "2021-03-24",
      "last_synced_at": "2026-10-02T02:36:15.243Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03411252"
    },
    {
      "nct_id": "NCT04666636",
      "title": "Mechanisms for Activation of Beige Adipose Tissue in Humans",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PreDiabetes"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron 50 MG",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron 100 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Philip Kern",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "35 Years to 65 Years"
      },
      "enrollment_count": 65,
      "start_date": "2020-12-07",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-07",
      "last_synced_at": "2026-10-02T02:36:15.243Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04666636"
    },
    {
      "nct_id": "NCT03187795",
      "title": "Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Spinal Cord Injuries",
        "Urinary Bladder, Neurogenic"
      ],
      "interventions": [
        {
          "name": "Oxybutynin Chloride IR",
          "type": "DRUG"
        },
        {
          "name": "Mirabegron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kessler Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 62,
      "start_date": "2019-04-03",
      "completion_date": "2022-03-30",
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-10-02T02:36:15.243Z",
      "location_count": 1,
      "location_summary": "West Orange, New Jersey",
      "locations": [
        {
          "city": "West Orange",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03187795"
    }
  ]
}